NurExone Biologic Ltd. Wins Healthcare Category at BOLD Awards VII and Partners with Investor Brand Network

NurExone Biologic Ltd., a company focused on developing biologically-guided exosome therapy for treating traumatic spinal cord injuries, secured first place in the healthcare category at the BOLD Awards VII. The recognition highlights the company’s advancements and contributions to the healthcare sector. Additionally, NurExone has partnered with Investor Brand Network (IBN) to enhance its awareness strategy among investors and stakeholders.

The BOLD Awards VII, an annual event celebrating innovation across various industries, acknowledged NurExone’s efforts in pioneering therapeutic solutions. The company’s work centers on leveraging exosome-based technology to address critical medical challenges such as spinal cord injuries. In conjunction with this accolade, NurExone announced its collaboration with IBN, a communications organization specializing in investor-focused outreach. This partnership aims to expand NurExone’s visibility within the investment community through targeted strategies and media engagement.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: April 1, 2026

Author

GOAI